Authors/Disclosures
|
Craig G. Campbell, MD
|
Dr. Campbell has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catabasis. Dr. Campbell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Solid. The institution of Dr. Campbell has received research support from Biogen. The institution of Dr. Campbell has received research support from Genzyme. The institution of Dr. Campbell has received research support from Acceleron, AMO, Biogen, Sarepta, Wave, PTC, Pfizer, Roche. |
|
Kenneth M. Attie, MD
(Acceleron Pharma)
|
No disclosure on file |
|
Jean K. Mah, MD, FRCPC, FAAN
(University of Calgary)
|
Dr. Mah has nothing to disclose. |
|
Mark Tarnopolsky, MD, PhD, FRCP
(McMaster University)
|
Dr. Tarnopolsky has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Tarnopolsky has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reneo. Dr. Tarnopolsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Tarnopolsky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reneo . Dr. Tarnopolsky has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Tarnopolsky has stock in Synaptive Medical. Dr. Tarnopolsky has stock in CloudDx. The institution of Dr. Tarnopolsky has received research support from Canadian Institute for Health Research. Dr. Tarnopolsky has received intellectual property interests from a discovery or technology relating to health care. |
|
Kathy Selby, MD
(U of BC Childrens Hospital)
|
The institution of Dr. Selby has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Selby has received research support from Biogen . The institution of Dr. Selby has received research support from Italfarmico. The institution of Dr. Selby has received research support from Reverogen. |
|
Steven Galetta, MD, FAAN
(NYU Langone Medical Center)
|
Dr. Galetta has nothing to disclose. |
|
Hugh J. McMillan, MD
(Children's Hospital of Eastern Ontario)
|
Dr. McMillan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis Gene Therapies. Dr. McMillan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Gene Therapies. The institution of Dr. McMillan has received research support from Roche. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Matthew L. Sherman, MD
|
No disclosure on file |
|
Diana M. Escolar, MD, FAAN
|
No disclosure on file |